GlassScriptPhysician profile
Marcin J Zuberek
NPI 1508397332
$27,820.06
in general payments reported to CMS, 2019-2025
35 companies · $9,248 in 2025
The $9,248 reported for 2025 was more than what 94% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.30 · 2023: $855 · 2024: $18K · 2025: $9,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $22K · Food and Beverage: $3,800 · Travel and Lodging: $1,641 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $22,071.43 |
| Food and Beverage | $3,799.86 |
| Travel and Lodging | $1,641.43 |
| Education | $284.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Central Indiana Urs Consumables, LLC | $22,071.43 | 2024-2025 | Dornier Medtech, Cvac Aspiration System, Dornier Medtech |
| Axonics, INC. | $1,575.99 | 2023-2024 | Axonics, Bulkamid |
| Medtronic, INC. | $870.18 | 2023-2025 | Altaviva, Interstim |
| Sumitomo Pharma America, INC. | $425.27 | 2023-2025 | Orgovyx, Gemtesa |
| Coloplast Corp | $419.84 | 2023-2025 | Speedicath, Virtue |
| Accord Healthcare, INC. | $279.20 | 2024-2025 | |
| Astellas Pharma US INC | $277.58 | 2024-2025 | Xtandi |
| Janssen Biotech, INC. | $274.85 | 2023-2025 | Erleada, Akeega |
| Procept Biorobotics Corporation | $172.72 | 2023-2024 | Aquabeam Robotic System, Aquabeam System |
| Pfizer INC. | $150.23 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $148.03 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $141.60 | 2024-2025 | Provenge |
| Boston Scientific Corporation | $134.48 | 2024-2025 | General - Kidney Stone Disease, Rezum Generator |
| Novartis Pharmaceuticals Corporation | $102.49 | 2023-2025 | |
| Urogen Pharma, INC. | $98.82 | 2024-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $72.59 | 2024-2025 | Eligard, Jatenzo |
| Telix Pharmaceuticals | $72.36 | 2023-2025 | Illuccix |
| Abbvie INC. | $71.79 | 2023-2025 | Botox |
| Myriad Genetic Laboratories, INC. | $61.03 | 2025 | Prolaris |
| Calyxo, INC. | $50.64 | 2024-2025 | Cvac Aspiration System |
| Progenics Pharmaceuticals, INC. | $38.15 | 2023-2025 | Pylarify |
| Halozyme INC | $33.68 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $32.60 | 2024-2025 | |
| Blue Earth Diagnostics | $25.02 | 2024 | |
| Merck Sharp & Dohme LLC | $24.91 | 2025 | Keytruda |
| Amgen INC. | $23.30 | 2022 | |
| Sun Pharmaceutical Industries INC. | $23.24 | 2023 | Yonsa |
| Endo Pharmaceuticals INC. | $21.92 | 2023 | Xiaflex, Aveed |
| Laborie Medical Technologies Corp. | $21.84 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Astrazeneca Pharmaceuticals LP | $19.59 | 2025 | Lynparza |
| Hologic Sales and Service, LLC | $19.57 | 2024 | Aptima |
| Ferring Pharmaceuticals INC. | $17.68 | 2025 | Adstiladrin |
| Olympus America INC. | $16.95 | 2025 | Itind System |
| Argon Medical Devices, INC. | $15.77 | 2025 | Clot Management |
| Immunitybio, INC. | $14.72 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$47,040.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcin Zuberek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.